[Clostridiodes difficile bacteraemia. First mexican case report].

Iván González-Godínez, Edgar Carrillo-Vázquez, Ana Laura Garduño-Ortíz, Sebastián Enrique Chacón-Hernández, Homero Antonio Hevia-Del Cabrera
{"title":"[Clostridiodes difficile bacteraemia. First mexican case report].","authors":"Iván González-Godínez, Edgar Carrillo-Vázquez, Ana Laura Garduño-Ortíz, Sebastián Enrique Chacón-Hernández, Homero Antonio Hevia-Del Cabrera","doi":"10.5281/zenodo.13306825","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clostridiodes difficile bacteremia (CDB) develops in less than 1% of all the cases, nonetheless, with a significant increase in mortality. The objective of the present article is to report the first case of CDB in the Mexican population, empathizing with the treatment difficulty derived from the lack of consensus.</p><p><strong>Clinical case: </strong>A 42-year-old female with previous history of chronic thromboembolic pathologies and grade III obesity, develops community acquired atypical pneumonia requiring hospitalization, having parenteral antibiotics. During hospitalization, non severe C. difficile infection was concluded and started treatment with Vancomycin for 10 days. One week later the patient presented to the emergency department at HES CMN SXXI with gastrointestinal symptomatology, mostly epigastric pain, fever and diarrhea. After proper approach, C. difficile was isolated in blood cultures through mass spectrophotometry analysis, for which a 10-day treatment of metronidazole was prescribed with resolution of the infection being discharged afterwards.</p><p><strong>Conclusions: </strong>CDB is an exceptional and lethal clinical condition, mainly seen in patients with previous gastrointestinal diseases. IV Metronidazole demonstrated therapeutic efficacy in this case report and could be a successful and available therapeutic option in Mexican health care units.</p>","PeriodicalId":94200,"journal":{"name":"Revista medica del Instituto Mexicano del Seguro Social","volume":"62 6","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista medica del Instituto Mexicano del Seguro Social","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5281/zenodo.13306825","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clostridiodes difficile bacteremia (CDB) develops in less than 1% of all the cases, nonetheless, with a significant increase in mortality. The objective of the present article is to report the first case of CDB in the Mexican population, empathizing with the treatment difficulty derived from the lack of consensus.

Clinical case: A 42-year-old female with previous history of chronic thromboembolic pathologies and grade III obesity, develops community acquired atypical pneumonia requiring hospitalization, having parenteral antibiotics. During hospitalization, non severe C. difficile infection was concluded and started treatment with Vancomycin for 10 days. One week later the patient presented to the emergency department at HES CMN SXXI with gastrointestinal symptomatology, mostly epigastric pain, fever and diarrhea. After proper approach, C. difficile was isolated in blood cultures through mass spectrophotometry analysis, for which a 10-day treatment of metronidazole was prescribed with resolution of the infection being discharged afterwards.

Conclusions: CDB is an exceptional and lethal clinical condition, mainly seen in patients with previous gastrointestinal diseases. IV Metronidazole demonstrated therapeutic efficacy in this case report and could be a successful and available therapeutic option in Mexican health care units.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[难辨梭状芽孢杆菌菌血症:墨西哥首例报告]。
背景:艰难梭菌菌血症(CDB)的发病率不到所有病例的 1%,但死亡率却显著上升。本文旨在报告墨西哥人群中的首例难辨梭状芽孢杆菌菌血症病例,并对因缺乏共识而导致的治疗困难表示同情:临床病例:一名 42 岁女性,既往有慢性血栓栓塞病史和 III 级肥胖症,患社区获得性非典型肺炎,需要住院治疗并使用肠外抗生素。住院期间发现了非严重的艰难梭菌感染,开始使用万古霉素治疗 10 天。一周后,患者因胃肠道症状(主要是上腹痛、发烧和腹泻)来到 HES CMN SXXI 急诊科就诊。经过适当处理后,通过质谱分析从血液培养物中分离出艰难梭菌,为此患者接受了为期10天的甲硝唑治疗,感染缓解后出院:CDB是一种特殊的致命性临床病症,主要见于既往患有胃肠道疾病的患者。在本病例报告中,静脉滴注甲硝唑显示出了疗效,可以成为墨西哥医疗机构的一种成功且可用的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Epidemiological and clinical aspects of Guilain-Barré syndrome, 2012-2022]. [Erythrocyte morphological alterations as predictors of kidney injury severity]. [HIV mortality trends in Mexico, 2000-2022]. [Risk of postoperative delirium in older adults under balanced general anesthesia]. [Workplace violence as a predictor of suicidal ideation in undergraduate internal physicians].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1